Consequently, the combined targeting of ATP6V0D2 with immunosuppressive agents could potentially enhance the potency of immunotherapy, thereby extending its benefits to a broader range of patients with advanced breast cancer, especially TNBC patients. The gene discussed is ATP6V0D2; the disease is breast carcinoma.